Jafron Biomedical announced that a new product, hemodialysis concentrate produced by Tianjin Standard Co., Ltd., a subsidiary, recently obtained the "Medical Device Registration Certificate" issued by the National Medical Products Administration(NMPA).

The new hemodialysis concentrate adopts a new formula, adding a glucose component to the general recipe. It is suitable for hemodialysis therapy of patients with acute and chronic renal failures，and can prevent hypoglycemia during this process.

So far, Jafron Biomedical has provided four different formulations of hemodialysis concentrate in China. With the enrichment of blood purification product portfolio and therapies, Jafron will further supply the treatment demands of hemodialysis patients.